Dianthus Therapeutics, Inc. /DE/ ($DNTH)
Filing Information
| Accession Number | 0001992260-26-000009 |
|---|---|
| Form Type | 4 |
| Filing Date | Sep 3, 2026 |
| Document | View SEC Filing |
Transactions
9
Total Shares
69,372
Total Value
$2,937,737.39
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP, Head of R&D | Common Stock | โ | Sep 1, 2026 | Exercise/Conversion | 7,500 | $17.88 | $134,100.00 | 11,500 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Sep 1, 2026 | Exercise/Conversion | 6,249 | $21.77 | $136,040.73 | 17,749 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Sep 1, 2026 | Exercise/Conversion | 9,375 | $22.07 | $206,906.25 | 27,124 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Sep 1, 2026 | Sale | 2,600 | $105.19 | $273,494.00 | 24,524 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Sep 1, 2026 | Sale | 7,215 | $106.25 | $766,593.75 | 17,309 | Direct | โ | View Details | |
EVP, Head of R&D | Common Stock | โ | Sep 1, 2026 | Sale | 13,309 | $106.74 | $1,420,602.66 | 4,000 | Direct | โ | View Details | |
EVP, Head of R&D | Stock Option (Right to Buy) | Derivative | Sep 1, 2026 | Exercise/Conversion | 7,500 | $0.00 | $0.00 | 56,776 | Direct | โ | View Details | |
EVP, Head of R&D | Stock Option (Right to Buy) | Derivative | Sep 1, 2026 | Exercise/Conversion | 6,249 | $0.00 | $0.00 | 41,676 | Direct | โ | View Details | |
EVP, Head of R&D | Stock Option (Right to Buy) | Derivative | Sep 1, 2026 | Exercise/Conversion | 9,375 | $0.00 | $0.00 | 87,500 | Direct | โ | View Details |